iOmx has been founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016. The Company has attracted leading international life science investors and closed a EUR 40 million Series A financing round only a few months after its inception. The proceeds will be used to advance proprietary product candidates up to initial clinical proof-of-concept.
iOmx will be supported by a high-profile team of reputed international scientists in the field of oncology, immunotherapy and clinical drug development who will serve on its Scientific Advisory Board (to be announced soon).
Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.
Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.